Sotatercept Explained: New Hope in Treating Pulmonary Arterial Hypertension │PHARMACOLOGY

Pulmonary arterial hypertension (PAH) can be a debilitating disease. This video dives into sotatercept, a new treatment option approved by the US Food and Drug Administration (FDA) in March 2024. We'll explore how it works, clinical trial results, and what it means for the future of PAH management.

Disclaimer: This YouTube channel is not intended to provide diagnosis, treatment, or medical advice. The content provided in this video is for informational purposes only. This should not be considered as a substitute for advice from a healthcare professional. Please consult with a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options. The statements made about specific products are not to diagnose, treat, cure, or prevent disease.

References:
1. Hassoun PM. Pulmonary Arterial Hypertension. N Engl J Med. 2021;385(25):2361-2376. doi:10.1056/NEJMra2000348
2. Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur Respir J. 2023;61(1):2201347. Published 2023 Jan 6. doi:10.1183/13993003.01347-2022
3. Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023;388(16):1478-1490. doi:10.1056/NEJMoa2213558

#pulmonaryarterialhypertension #PulmonaryVascularDisease #Sotatercept #Winrevair #MedicalBreakthrough #Pharmacology #NewTreatment